Etelcalcetide: A New Intravenous Calcimimetic for the Treatment of Secondary Hyperparathyroidism in Haemodialysis Patients

Abstract

Etelcalcetide hydrochloride (also known as AMG 416) is a new, second generation, long-acting calcimimetic agent that is administered intravenously. In November 2016 it received its first approval in the UE for the treatment of secondary hyperparathyroidism (SHPT) in adult haemodialysis patients. This article summarizes the results of pre-clinical and clinical studies which demonstrated that Etelcalcetide decreases effectively PTH levels. Although questions about this new compound remain open, and further studies are required to assess clinical hard outcomes as well as long term efficacy and safety, Etelcalcetide represents a new therapeutic option for the challenging treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).